Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?

To: Mark Fowler who wrote (86253)	12/5/1999 5:38:00 PM
From: Bill Harmond	Read Replies (1) \| Respond to of 164684

To tell you the truth, I don't know.

To: Mark Fowler who wrote (86253)	12/5/1999 11:47:00 PM
From: Libbyt	Read Replies (1) \| Respond to of 164684

AFFIX... This information is from the Bull Market Portfolio...I am probably one of the very few people who do not like the companies dealing with genetic issues. I am certain that science will move forward and provide some wonderful new insights that will be helpful to humanity. However, I would think that these companies have some economic uncertainty. If a company came up with a specific "cure" or use of a gene, public pressure would be intense to have this available to everyone at a low cost. The morality issues that some people raise about using human genes is incredible. Do you know that the State of California has a Governor's Select Advisory Committee on Human Cloning? (The first state that I know of to have such a committee.) Some of the members of this Committee are brilliant and I'm sure their guidelines will not affect any of these companies...however it has brought to my attention the very controversial nature of cloning, and using human genes to fight specific illnesses. (I'm all for correctly using human genes...but there are numerous very vocal people against using any type of gene therapy.) Libbyt "THE BULL MARKET REPORT DRUG AND BIOTECH PORTFOLIO" MID CAP BIOTECH COMPANIES AFFYMETRIX, INC. (NASDAQNM:AFFX) Affymetrix manufactures and sells instrumentation for acquiring, analyzing, and managing complex genetic data, based on proprietary GeneChip(R) technology. This is the type of technology that will help to bring rapid genetic-based diagnosis and treatment into everyday use in the future. In addition to manufacturing devices, the company holds valuable intellectual property and can increase revenues through licensing of patents. In the first half of 1999, product sales increased 150% over 1998 levels. AFFX is a proven leader in the field and has consistently developed highly innovative technology that helps to drive the biotechnology field. Affymetrix may become a gorilla in the biotechnology instrumentation arena. Excerpts from the company's Q2 1999 financial report: For the quarter ended June 30, 1999, revenue increased 96% to $22 million, up from revenue of $11 million for the quarter ended June 30, 1998. For the first six months of 1999, revenue increased 90% to $40 million, up from revenue of $21 million for the first six months of 1998. The increase in product sales during the quarter and six months of 1999 compared to the same periods in 1998, resulted from the growth in placements of GeneChip(R) systems together with the accompanying sales of GeneChip probe arrays and related products and subscription fees. The company reported a net loss of $7.8 million, or $0.32 per share for the quarter ended June 30, 1999, compared to a net loss of $6.6 million, or $0.29 per share, for the same period in 1998. Employees: 321 Affymetrix, Inc. 3380 Central Expressway Santa Clara, CA 95051 Telephone: 408.731.5000 Fax: 408.481.0422 Website: www.affymetrix.com Key Data: Market Capitalization: $2.5 billion Shares Outstanding: 24 million Float: 15 million Institutional Ownership: 9% 1999 Projected EPS: -$1.10 2000 Projected EPS: -$0.25 5 Year Projected Annual Growth Rate: 55% Last update: Nov. 1999